Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene remedy maker Kelonia Therapeutics for at the least $3.25 billion, the businesses introduced Monday.
The acquisition will grant Indianapolis-based Lilly entry to Kelonia’s blood most cancers remedy referred to as KLN-1010 that genetically modifies sufferers’ immune cells with out requiring them to be faraway from the physique. The immune cells are reprogrammed to assault the most cancers cells in a remedy often called CAR-T.
“The early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia’s platform,” mentioned Jacob Van Naarden, government vice chairman and president of Lilly Oncology and head of company enterprise growth.
The partnership will place Kelonia’s remedy strategy to “broaden the reach of cell therapy beyond the current CAR-T landscape,” Kelonia CEO Kevin Friedman mentioned in a press release. The firms plan to use the know-how to finally deal with a variety of cancers and different illnesses.
Lilly can pay Kelonia $3.25 billion in money, though Kelonia may rise up to $7 billion for hitting sure medical and business milestones, Lilly mentioned in a press release. Kelonia has 62 staff, most of whom are primarily based in Boston.
Lilly, booming from gross sales of its blockbuster Zepbound weight-loss injection, has been closely investing in Boston-area biotechs in latest months. The Kelonia deal, which is about to shut within the second half of 2026, will mark at the least the third acquisition of a Massachusetts firm by Lilly this 12 months.
In February, Lilly introduced plans to purchase Watertown biotech Orna Therapeutics for up to $2.4 billion. Orna equally makes a speciality of know-how to flip a affected person’s cells into cell therapies with out eradicating them from the physique. Orna hopes to use CAR-T therapies to deal with autoimmune illnesses.
A month later, Lilly introduced it could acquire Centessa Pharmaceuticals, a narcolepsy drug maker with its US headquarters in Boston, in a deal value about $6.3 billion.
Lilly has additionally entered into quite a lot of partnerships with native firms to develop remedies for a variety of situations.
Boston biotech Nimbus Therapeutics is working with Lilly to develop a new oral obesity treatment in an effort to lengthen Lilly’s success within the weight problems drug market. Nimbus is eligible to obtain $55 million within the close to time period and up to $1.3 billion in complete, pending sure growth and gross sales milestones.
Lilly can be partnering with Cambridge firm Repertoire Immune Medicines to develop autoimmune illness therapies. As a part of the deal — value $85 million upfront and up to $1.84 billion complete — Repertoire will develop up to three drug candidates and Lilly will lead the candidates by means of medical growth, manufacturing, and commercialization.
In 2024, Lilly opened a $700 million research and development center within the Fort Point neighborhood of Boston. At the time, the corporate mentioned it deliberate to finally make use of about 500 staff there.
Marin Wolf could be reached at marin.wolf@globe.com.
